Physiological platelet-endothelium and platelet-subendothelium interactions

Physiological platelet-endothelium and platelet-subendothelium interactions represent the fundamental biological processes governing hemostasis and thrombosis. Under normal physiological conditions, the vascular endothelium maintains an antithrombotic surface by secreting nitric oxide and prostacyclin, which inhibit platelet activation (StatPearls, NBK545263). However, when the vessel wall is injured, the subendothelial matrix—containing collagen and von Willebrand factor (vWF)—is exposed, triggering immediate platelet tethering and adhesion via the Glycoprotein Ib-IX-V complex and Glycoprotein VI receptor (PubMed, 15153453). This initial interaction leads to intracellular signaling, platelet shape change, and the release of agonists like ADP and thromboxane A2, which amplify the recruitment of additional platelets. The final common pathway of this process is the activation of the integrin alpha-IIb/beta-3 (GPIIb/IIIa), which facilitates platelet-platelet aggregation by binding fibrinogen (Nature Reviews, nri2048). While essential for wound healing, pathological activation of these interactions can lead to occlusive thrombus formation, resulting in myocardial infarction or stroke. Therapeutic strategies often target specific molecular components of these interactions, such as P2Y12 receptors or COX-1, to manage cardiovascular risk (PubMed, 11110600).

Other names

Platelet adhesionPlatelet-vessel wall interactionHemostasisThrombosisPlatelet-subendothelium interactionPlatelet-endothelium interaction

Inhibition of platelet activation and aggregation through various pathways, including COX-1 inhibition, P2Y12 receptor antagonism, Glycoprotein IIb/IIIa blockade, and PAR-1 antagonism.